CDC grand rounds: Family history and genomics as tools for cancer prevention and control

Morbidity and Mortality Weekly Report

Volumn 65, Issue 46, 2016, Pages 1291-1294

  Rodriguez, Juan L ^a   Thomas, Cheryll C ^a   Massetti, Greta M ^a   Duquette, Debra ^b   Avner, Lindsay ^c   Iskander, John ^a   Khoury, Muin J ^d   Richardson, Lisa C ^a  

^a CENTERS FOR DISEASE CONTROL AND PREVENTION   (United States)

^b Michigan Department of Health and Human Service   (United States)

^c Bright Pink   (United States)

^d NATIONAL CENTER ON BIRTH DEFECTS AND DEVELOPMENTAL DISABILITIES   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANAMNESIS; BREAST NEOPLASMS; COLORECTAL NEOPLASMS, HEREDITARY NONPOLYPOSIS; COMMUNITY CARE; FEMALE; FORECASTING; GENETICS; GENOMICS; GOVERNMENT; HUMAN; NEOPLASMS; OVARIAN NEOPLASMS; PUBLIC HEALTH SERVICE; TRENDS; UNITED STATES;

BREAST NEOPLASMS; COLORECTAL NEOPLASMS, HEREDITARY NONPOLYPOSIS; COMMUNITY HEALTH SERVICES; FEDERAL GOVERNMENT; FEMALE; FORECASTING; GENOMICS; HUMANS; MEDICAL HISTORY TAKING; NEOPLASMS; OVARIAN NEOPLASMS; PUBLIC HEALTH PRACTICE; STATE GOVERNMENT; UNITED STATES;

EID: 85005965519     PISSN: 01492195     EISSN: 1545861X     Source Type: Journal    
DOI: 10.15585/mmwr.mm6546a3     Document Type: Note

References (15)

1. Moyer VA; US Preventive Services Task Force. Risk assessment, genetic counseling, and genetic testing for BRCA-related cancer in women: US Preventive Services Task Force recommendation statement. Ann Intern Med 2014;160:271–81.
2. Petrucelli N, Daly MB, Feldman GL. BRCA1 and BRCA2 hereditary breast and ovarian cancer. In: Pagon RA, Adam MP, Ardinger HH, et al., eds. GeneReviews [Internet]. Seattle, WA: University of Washington, Seattle; 2013. http://www.ncbi.nlm.nih.gov/books/NBK1247/
3. Nelson HD, Fu R, Goddard K, et al. Risk assessment, genetic counseling, and genetic testing for BRCA-related cancer: systematic review to update the U.S. Preventive Services Task Force recommendation evidence synthesis no. 101. Agency for Healthcare Research and Quality publication no. 12–05164-EF-1. Rockville, MD: Agency for Healthcare Research and Quality; 2013.
4. Antoniou A, Pharoah PD, Narod S, et al. Average risks of breast and ovarian cancer associated with BRCA1 or BRCA2 mutations detected in case series unselected for family history: a combined analysis of 22 studies. Am J Hum Genet 2003;72:1117–30. http://dx.doi.org/10.1086/375033
5. Chen S, Parmigiani G. Meta-analysis of BRCA1 and BRCA2 penetrance. J Clin Oncol 2007;25:1329–33. http://dx.doi.org/10.1200/JCO.2006.09.1066
6. Moyer VA; US Preventive Services Task Force. Medications for risk reduction of primary breast cancer in women: US Preventive Services Task Force recommendation statement. Ann Intern Med 2013;159:698–708.
7. Kohlmann W, Gruber SB. Lynch syndrome. In: Pagon RA, Adam MP, Ardinger HH, et al., eds. GeneReviews [Internet]. Seattle WA: University of Washington, Seattle; 2014. http://www.ncbi.nlm.nih.gov/books/NBK1211/
8. Kaz AM, Brentnall TA. Genetic testing for colon cancer. Nat Clin Pract Gastroenterol Hepatol 2006;3:670–9. http://dx.doi.org/10.1038/ncpgasthep0663
9. Palomaki GE, McClain MR, Melillo S, Hampel HL, Thibodeau SN. EGAPP supplementary evidence review: DNA testing strategies aimed at reducing morbidity and mortality from Lynch syndrome. Genet Med 2009;11:42–65. http://dx.doi.org/10.1097/GIM.0b013e31818fa2db
10. Evaluation of Genomic Applications in Practice and Prevention (EGAPP) Working Group. Recommendations from the EGAPP Working Group: genetic testing strategies in newly diagnosed individuals with colorectal cancer aimed at reducing morbidity and mortality from Lynch syndrome in relatives. Genet Med 2009;11:35–41. http://dx.doi.org/10.1097/GIM.0b013e31818fa2ff
11. Trivers KF, Rodriguez JL, Cox SL, Crane BE, Duquette D. The activities and impact of state programs to address hereditary breast and ovarian cancer, 2011–2014. Healthcare 2015;3:948–63. http://dx.doi.org/10.3390/healthcare3040948
12. Dotson WD, Douglas MP, Kolor K, et al. Prioritizing genomic applications for action by level of evidence: a horizon-scanning method. Clin Pharmacol Ther 2014;95:394–402. http://dx.doi.org/10.1038/clpt.2013.226
13. Khoury MJ, Bowen MS, Burke W, et al. Current priorities for public health practice in addressing the role of human genomics in improving population health. Am J Prev Med 2011;40:486–93. http://dx.doi.org/10.1016/j.amepre.2010.12.009
14. Khoury MJ, Galea S. Will precision medicine improve population health? JAMA 2016;316:1357–8. http://dx.doi.org/10.1001/jama.2016.12260
15. McCarthy AM, Bristol M, Domchek SM, et al. Health care segregation, physician recommendation, and racial disparities in BRCA1/2 testing among women with breast cancer. J Clin Oncol 2016;34:2610–8. http://dx.doi.org/10.1200/JCO.2015.66.0019